MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.95% | -22.19% | -14.03% | -4.69% | -5.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.36% | -44.23% | -37.82% | -28.99% | -25.94% |
| Operating Income | 43.36% | 44.23% | 37.82% | 28.99% | 25.94% |
| Income Before Tax | 51.98% | 44.36% | 34.23% | 20.52% | 19.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.98% | 44.36% | 34.23% | 20.52% | 19.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.98% | 44.36% | 34.23% | 20.52% | 19.77% |
| EBIT | 43.36% | 44.23% | 37.82% | 28.99% | 25.94% |
| EBITDA | 44.03% | 44.66% | 38.20% | 29.38% | 26.31% |
| EPS Basic | 55.52% | 46.74% | 36.06% | 22.20% | 21.36% |
| Normalized Basic EPS | 48.42% | 46.25% | 35.63% | 29.80% | 28.50% |
| EPS Diluted | 46.19% | 46.93% | 36.28% | 22.46% | 21.05% |
| Normalized Diluted EPS | 48.42% | 46.25% | 35.63% | 29.80% | 28.50% |
| Average Basic Shares Outstanding | 9.79% | 6.73% | 3.61% | 2.19% | 2.04% |
| Average Diluted Shares Outstanding | 9.79% | 6.73% | 3.61% | 2.19% | 2.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
